- H99 -

Powering research to treat Friedreichs Ataxia Dear FA family Although the circumstances of our meeting are difficult we are glad that you have found the Friedreich039s Ataxia Research Alliance. Leading to the discovery and advancement of treatments for FA Join a passionate community and change the course of this rare disease Apply for a research grant and make an impact Work with an experienced research community Utilize FARA resources to help optimize the pace of research Fuel research progress Share your story Engage with our amazing community Latest news from our community. March 2025 Advocacy Newsletter Press Release Community Update Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results SKYCLARYS omaveloxolone Approval by Health Canada Ushers in a New Era for Friedreichs Ataxia Treatment in Canada Design Therapeutics Initiated Phase 1 Single Ascending Dose Trial of DT216P2 in Healthy Volunteers FA Community Statement from Biogen Press Release Community Statement PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich039s Ataxia February 2025 Advocacy Newsletter Job Posting Development Manager Major Gifts Letter to the FA Community from Astellas Pharma Webinar Recording PTC Therapeutics Vatiquinone Program January 2025 Update Janaury 2025 Advocacy Newsletter 95 Million 1 18 1500 198. 5M 38 Our upcoming events.